Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

Roy S. Herbst, Masahiro Tsuboi, Damien Urban et al.|Journal of Clinical Oncology|2023

Cited by 386